Randomized, open-label, phase three study comparing flutamide and abiraterone in patients with advanced prostate cancer after failure of first combined androgen blockade therapy.

Randomized, open-label, phase three study comparing flutamide and abiraterone in patients with advanced prostate cancer after failure of first combined androgen blockade therapy. - Randomized, open-label, phase three study comparing flutamide and abiraterone in patients with advanced prostate cancer after failure of first combined androgen blockade therapy.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016617

Enrollment

Registered

2015-02-25

Start date

2015-02-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Patients assigned to receive flutamide therapy. Patients assigned to receive abiraterone therapy.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Advanced prostate cancer patients after failure of first combined androgen blockade therapy. Eastern Cooperative Oncology Group performance status of 0 to 2.

Exclusion criteria

Exclusion criteria: Patients who have other active cancer, infection diseases or glaucome are excluded.

Design outcomes

Primary

Measure	Time frame
Biochemical-free Survival rate	—

Countries

Japan

Contacts

Public ContactRyosuke Ando

Nagoya City University Graduate School of Medical Sciences Department of Nephro-urology

ryo@med.nagoya-cu.ac.jp052-853-8266

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026